COST-EFFECTIVENESS OF LEVETIRACETAM FOR PATIENTS WITH JUVENILE MYOCLONIC EPILEPSY- A MODELING APPROACH BY THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE.
Author(s)
Kayo M1, Rosim RP2, Duva A2, Ballalai Ferraz AF2, Carmo E1
1UCB Biopharma LTDA, São Paulo, Brazil, 2QuintilesIMS, São Paulo, Brazil
OBJECTIVES: Sodium valproate is the recommended antiepileptic drug (AED) in the Brazilian public Healthcare System (SUS) for the treatment of juvenile myoclonic epilepsy (JME). However, approximately 30% of patients do not achieve a satisfactory control with valproate, raising the need for add-on AEDs. Levetiracetam is the only AED with labeled indication for JME, but it is not included in the SUS formularies. This study aimed to assess the cost-effectiveness and additionally the budget impact (BI) of levetiracetam for patients with JME in comparison with the SoC METHODS: A 16-week decision tree was developed with three health states: response; lack of response and death. Efficacy, QoL and transition probabilities assumptions came from a randomized trial RESULTS: The total number of patients with JME calculated was 44,616. From these, we assumed that 4,698 (10%) would be taking levetiracetam in the fifth year. The inclusion of levetiracetam would cost an additional BRL 43.6 million, between years 1 and 5, reaching BRL 16.3 million in the fifth year. The calculated ICER was BRL 5,882 /year / response. The ICUR calculated was BRL 58,294 /QALY. The probabilistic sensitivity analysis confirmed the results, demonstrating that levetiracetam was cost-effective in 90% of simulations. CONCLUSIONS: Levetiracetam is a cost-effective treatment option as add-on AED for the treatment of JME, from the perspective of Brazilian Public Health System. Reference: 1-Noachtar S, et al. Neurology: 607–16.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PND30
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Neurological Disorders